C.R. Bard, Inc. (BCR)

Looks like a good value and the baby boomers could keep the fueling the growth.

Low debt, high profit margins for the industry (just under 20%) and a nice steady increase in Total Cash from Operations down through the years. Operating expenses have also risen over the same period, but not as much indicating that management have a good handle on things. I think the impact of the Obama plan is already built into the current price, so I don't expect a lift from that.

This High Quality manufacturer of medical devices has a QVT Rating of 9.93

7 day long trade

high roe, good debt position

2/122 in Health Care Equipment -(70.4@B/A-)

BofD, z3, pt92, analrep

Ford Strong Buy, S&P (4 or 3 stars), Member of S&P 500

BABY BOOMERS ARE AGING AND THIS IS A MEDICAL SUPPLY COMPANY THAT HAS FOLLOWED THE GILLETTE MODEL.....USE IT, DISPOSE IT, REPLACE IT. HEART, UROLOGY, ETC.ETC.ETC.ETC.

earnings, sales, PE, growth from Obama

Intrinsic value of $93.83

One of the 52 S&P500 Dividend Aristocrats. Competitors include BAX and BSX. At 70$ BCR is not that cheap at all, but it's a quality company, which will do well in the long run and for the short term, when the current April bull run is over.

Low beta (0.36). Gross margin (62%), P/E (18), growth (9.5% CAGR), S&P IQ (223/250) and EPS all beat the industry. Healthcare shares (patient care devises & supplies) give me portfolio balance in a sector expected to perform well in a recessionary economy. Low debt (0.08).

At $72, shares are near historic lows. I bought 4/22 and today at average of $73.97, so I’m obviously not the best market timer. But S&P gives BCR 5 stars (Strong Buy); Reuters rates it “Outperform” and FirstCall has it “Buy”; ValueLine has it top rated for Timeliness and Safety. The Motley Fool Community gives it 4 of 5 stars. MSN Money rates it 7 out of 10 (“Hold”) with the following commentary:

“Pro: Earnings growth in the past year is holding steady compared to earnings growth in the past three years. Neutral
Shares are under heavy accumulation by financial institutions. Positive for large companies like BCR

Con: The StockScouter measure of relative price change and consistency is low. Negative
One or more analysts has modestly decreased quarterly earnings estimates for BCR. Negative.

BCR’s chart is boringly steady …up until April 2008. But it still outperforms the S&P 500. If losing less money is your objective, this is a stock for you. If share price appreciation in the next year is your objective, I think you should be comfortable piling onto C.R. Bard at these prices.

Dave

Never thought I would say this but darned if you do and damed if you did not

everyone needs medical supplies

A top ranking S&P 500 Dividend Aristocrat.

Consistency, nice current and quick ratios. Should see a modest but predictable increase in the next four years.

ibd

This hit a 52 week low today.

Another quality company thrown in the trash during this panic.